 | Up a level |
2022
Laakmann, E., Riecke, K., Neunhoeffer, T., Park-Simon, T-W., Weide, R., Polasik, A., Schmidt, M., Puppe, J., Fasching, P. A., Hesse, T., Decker, T., Denkert, C., Fehm, T. N., Nekljudova, V., Rey, J., Loibl, S., Mueller, V. and Witzel, I. (2022). Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry. Ann. Oncol., 33 (7). S. S660 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Laakmann, E., Riecke, K., Neunhoeffer, T., Park-Simon, T-WP, Weide, R., Polasik, A., Schmidt, M., Puppe, J., Fasching, P. A., Hesse, T., Decker, T., Denkert, C., Fehm, T., Nekljudova, V, Rey, J., Loibl, S., Mueller, V and Witzel, I (2022). Long-term survival of HER2-positive breast cancer patients with brain metastases: subanalysis of the BMBC Registry. Geburtshilfe Frauenheilkd., 82 (10). S. E113 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Laakmann, E., Witzel, I, Neunhoeffer, T., Park-Simon, T-W, Weide, R., Riecke, K., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., Lubbe, K., Hesse, T., Thill, M., Zahm, D-M, Denkert, C., Fehm, T., Nekljudova, V, Rey, J., Loibl, S. and Mueller, V (2022). Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry. ESMO Open, 7 (3). AMSTERDAM: ELSEVIER. ISSN 2059-7029
2021
Laakmann, E., Witzel, I., Neunhoeffer, T., Park-Simon, T-W., Weide, R., Riecke, K., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., Luebbe, K., Hesse, T., Thill, M., Zahm, D-M., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S. and Mueller, V. (2021). Characteristics of patients with brain metastases from HER2-positive breast cancer. Ann. Oncol., 32. S. S63 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2018
Hauke, J., Hahnen, E., Burges, A., Reuss, A., Gregorio, N. D., El-Balat, A., Richters, L., Hilpert, F., Schmidt, S., Meier, W., Gevensleben, H., Heubner, M., Dietrich, D., Kast, K., Braicu, E., Neunhoeffer, T., Schmutzler, R. K. and Harter, P. (2018). Prevalence of somatic mutations in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1 study). Oncol. Res. Treat., 41. S. 90 - 92. BASEL: KARGER. ISSN 2296-5262
2016
Sehouli, J., Mahner, S., Neunhoeffer, T., Harter, P., de Gregorio, N., Fridrich, C., Markmann, S., Richter, R., Potenberg, J., Lorenz, R., Schmidt, M., Doering, G., Belau, A., Lueck, H. J., Chekerov, R., du Bois, A. and Hilpert, F. (2016). Topotecan (T) +/- Sorafenib (S) for platinum-resistant ovarian cancer (PROC): results of doubleblind placebo-controlled randomized NOGGO - AGO intergroup trial. Int. J. Gynecol. Cancer, 26. S. 2 - 4. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438